ES2060001T3 - Un procedimiento de manufactura de particulas en polvo para administracion oral en forma fluida; de sustancias biologicamente activas. - Google Patents

Un procedimiento de manufactura de particulas en polvo para administracion oral en forma fluida; de sustancias biologicamente activas.

Info

Publication number
ES2060001T3
ES2060001T3 ES90203430T ES90203430T ES2060001T3 ES 2060001 T3 ES2060001 T3 ES 2060001T3 ES 90203430 T ES90203430 T ES 90203430T ES 90203430 T ES90203430 T ES 90203430T ES 2060001 T3 ES2060001 T3 ES 2060001T3
Authority
ES
Spain
Prior art keywords
powder
procedure
oral administration
biologically active
active substances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90203430T
Other languages
English (en)
Inventor
Gerrit Bernardus Maria Beuving
Nijs Henrik De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo NV
Original Assignee
Akzo NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo NV filed Critical Akzo NV
Application granted granted Critical
Publication of ES2060001T3 publication Critical patent/ES2060001T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE PRESENTAN PARTICULAS PULVERIZADAS O GRANULOS UTILES PARA LA PREPARACION DE CIERTOS COMPUESTOS PSICOTROPICOS (EJ. MIAUSESINA Y MIRTACEPINA). LAS SUSPENSIONES RESULTANTES, Y BASTANTE INSIPIDAS, NO TIENEN UN EFECTO ANESTESICO LOCAL Y SON FACILES DE SUSPENDER. LOS GRANULOS CONTIENEN EL COMPUESTO PSICOTROPICO, UN DERMATIVO DE CELULOSA, UN POLIMERO Y UNA SUSTANCIA PARA RELLENAR.
ES90203430T 1989-12-30 1990-12-19 Un procedimiento de manufactura de particulas en polvo para administracion oral en forma fluida; de sustancias biologicamente activas. Expired - Lifetime ES2060001T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL8903199 1989-12-30

Publications (1)

Publication Number Publication Date
ES2060001T3 true ES2060001T3 (es) 1994-11-16

Family

ID=19855853

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90203430T Expired - Lifetime ES2060001T3 (es) 1989-12-30 1990-12-19 Un procedimiento de manufactura de particulas en polvo para administracion oral en forma fluida; de sustancias biologicamente activas.

Country Status (14)

Country Link
US (1) US5238688A (es)
EP (1) EP0436252B1 (es)
JP (1) JP3051459B2 (es)
KR (1) KR0156735B1 (es)
AT (1) ATE93136T1 (es)
AU (1) AU634614B2 (es)
CA (1) CA2033418C (es)
DE (1) DE69002822T2 (es)
DK (1) DK0436252T3 (es)
ES (1) ES2060001T3 (es)
IE (1) IE63986B1 (es)
NZ (1) NZ236626A (es)
PT (1) PT96401B (es)
ZA (1) ZA9010452B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328688A (en) * 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
ES2212550T3 (es) * 1998-04-02 2004-07-16 Akzo Nobel N.V. Solucion oral liquida que comprende el antidepresor mirtazapina.
US6492320B2 (en) * 1999-09-24 2002-12-10 Rohm And Hass Company Multifunctional, granulated pellet aid and process
TWI256309B (en) * 1999-10-13 2006-06-11 Akzo Nobel Nv New formulation of mirtazapine
EP1251854A2 (en) * 2000-01-19 2002-10-30 Akzo Nobel N.V. Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
MXPA04008720A (es) * 2002-03-12 2004-12-06 Squibb Bristol Myers Co Suspension oral de sabor agradable y metodo.
US7632521B2 (en) * 2003-07-15 2009-12-15 Eurand, Inc. Controlled release potassium chloride tablets
US7838029B1 (en) 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
EP1689371A2 (en) * 2003-11-25 2006-08-16 Aurobindo Pharma Limited Pharmaceutical compositions of mirtazapine
DE102004034043A1 (de) * 2004-07-13 2006-02-09 Krka Tovarna Zdravil, D.D. Feste pharmazeutische Zusammensetzung, die Mirtazapin enthält
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4128641A (en) * 1975-07-31 1978-12-05 Hzi Research Center Inc. Tetracyclic psychotropic drug
NL7809726A (nl) * 1978-09-26 1980-03-28 Akzo Nv Nieuwe tetracyclische verbindingen.
JPS5665825A (en) * 1979-10-31 1981-06-03 Mochida Pharmaceut Co Ltd Remedy for peptic ulcer
US4623588A (en) * 1984-02-06 1986-11-18 Biotek, Inc. Controlled release composite core coated microparticles
US4870060A (en) * 1985-03-15 1989-09-26 Janssen Pharmaceutica Derivatives of γ-cylodextrin
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
ES2038669T3 (es) * 1986-09-18 1993-08-01 London School Of Pharmacy Innovations Ltd Formulacion farmaceutica.
DE3856555T2 (de) * 1987-10-16 2004-04-29 Elan Corp. Plc Diltiazem-Zusammensetzungen mit kontrollierter Wirkstoffabsorption
EP0319061A1 (en) * 1987-11-28 1989-06-07 Akzo N.V. Medicament with antiemetic action

Also Published As

Publication number Publication date
NZ236626A (en) 1992-10-28
JPH04210638A (ja) 1992-07-31
PT96401A (pt) 1991-10-15
CA2033418C (en) 2002-05-14
CA2033418A1 (en) 1991-07-01
DE69002822D1 (de) 1993-09-23
EP0436252A1 (en) 1991-07-10
KR0156735B1 (ko) 1998-11-16
AU6839890A (en) 1991-07-04
US5238688A (en) 1993-08-24
JP3051459B2 (ja) 2000-06-12
PT96401B (pt) 1998-06-30
IE63986B1 (en) 1995-06-28
KR910011266A (ko) 1991-08-07
IE904531A1 (en) 1991-07-03
ZA9010452B (en) 1991-10-30
ATE93136T1 (de) 1993-09-15
EP0436252B1 (en) 1993-08-18
AU634614B2 (en) 1993-02-25
DE69002822T2 (de) 1993-12-23
DK0436252T3 (da) 1993-12-27

Similar Documents

Publication Publication Date Title
AU584549B2 (en) Pharmaceutical compositions containing hollow fine tubular drug delivery systems
PL357144A1 (pl) Nowe postaci dawki podstawionego benzimidazolu oraz sposoby ich zastosowania
DE69931498D1 (de) Oral zersetzbare tablette mit ausbildung eines zähen schleims
ES2159524T3 (es) Preparacion farmaceutica para administrarse en el interior de las vias respiratorias.
SE8703034D0 (sv) Oralt terapeutiskt system med systemisk verkan
ES2036457B1 (es) Forma de dosificacion farmaceutica solida oral de liberacion programada y procedimiento de preparacion.
ES2052016T3 (es) Composicion emulsionada.
ES2149164T3 (es) Nanoparticulas de farmacos de superficie modificada.
AR020051A1 (es) Procedimiento de uso y uso de una combinacion de un anticuerpo anti-erbb2 y un agente quimicoterapeutico distinto de un derivado de antraciclina para la manufactura de un medicamento util para el tratamiento de cancer
KR890700125A (ko) 신규 벤즈이미다졸 유도체, 그 제조방법 및 이 화합물을 함유하는 제약 조성물
DE69519685D1 (de) Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
SE8804628D0 (sv) New compounds
ATE295151T1 (de) Sprühbeschichtete mikropartikel für nadellose spritzen
SE9704400D0 (sv) Porous inorganic particles as carriers for drug substances
DE58906232D1 (de) Azelastin enthaltende Arzneimittel mit kontrollierter Wirkstoffabgabe.
SE8400723D0 (sv) Farmaceutisk komposition
ATE93136T1 (de) Pharmazeutische zubereitung zur oralen verabreichung in fluessiger form.
EE03954B1 (et) Toimeaine pärsitud vabanemisega karbamasepiini ravimvormi valmistamise meetod
ATE85213T1 (de) Einen wirkstoff und ein in wasser quellendes polymer enthaltendes arzneimittel.
ATE256134T1 (de) Sulfatierte phosphatidylinositole, ihre herstellung und verwendung
CO5170463A1 (es) Formas polimorfas de un citrato de azobiciclo [2,2,2]octan- 3-amina y sus composiciones farmaceuticas
JPS6463521A (en) Trapidyl-containing drug composition, manufacture and related therapeutical use
DE68907091D1 (de) Scleroglucan und wirkstoff enthaltende pharmazeutische tabletten und kapselgranulate.
CO4230076A1 (es) Proceso de infusion termica para preparar formas de medica- mentos de dosis solidas con liberacion controlada para ad- ministracion oral y los medicamentos preparados mediante es- te proceso.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 436252

Country of ref document: ES